In line with the previously reported finding that CPT1A inhibition in melanoma cells reactivates MAPKi-suppressed glycolysis and counteracts the BRAFi growth inhibitory effect11, ETO was ineffective when added early on during the treatment (Fig. 1d). The gene discussed is CPT1A; the disease is melanoma.